Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study
Melissa Lagger, Hugo Najberg, Almir Miftaroski, Lucien Widmer, Sara Di Renzo, Pouya Iranmanesh, Maxime Matter, Boran Tekdogan · 2026
Read Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study by Melissa Lagger, Hugo Najberg, Almir Miftaroski, Lucien Widmer, Sara Di Renzo, Pouya Iranmanesh, Maxime Matter, Boran Tekdogan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357577.txt.
Description
Melissa Lagger and coauthors published a 2026 protocol in PLOS ONE for a Swiss cohort study on a timely question. Do GLP-1 receptor agonists, the blockbuster diabetes and weight-loss drugs, affect pancreatic cysts that can turn cancerous?? These cysts, called IPMNs, are increasingly common findings, and the same drugs are now taken by millions, yet their effect on existing pancreatic lesions is unknown. Three Swiss hospitals will pool records from 2010 to mid-2026.
Patients will be sorted into four groups by drug exposure and cyst status, and cyst progression will be judged by international radiological criteria. The study also tracks tumor markers, pancreatitis episodes, progression to advanced precancer or cancer, and operations triggered. The authors are frank about limits: with only a few dozen patients expected in the key group, the study may be too small for firm answers. Even so, a carefully measured signal beats the current evidence vacuum.
Catalog record
| CREATOR | Melissa Lagger, Hugo Najberg, Almir Miftaroski, Lucien Widmer, Sara Di Renzo, Pouya Iranmanesh, Maxime Matter, Boran Tekdogan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17519 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |